心臓弁膜症:世界の治験レビュー(2017年下半期版)

【英語タイトル】Heart Valve Disease Global Clinical Trials Review, H2, 2017

GlobalDataが出版した調査資料(GDHC4545CTIDB)・商品コード:GDHC4545CTIDB
・発行会社(調査会社):GlobalData
・発行日:2017年9月1日
・ページ数:136
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥260,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD5,000 ⇒換算¥520,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD7,500 ⇒換算¥780,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、世界における心臓弁膜症治療の臨床試験動向について調査・分析し、アジア/ヨーロッパ/アメリカ/中南米の主要国における治験件数、フェーズ別の治験件数、進捗状況別の治験件数、有望なスポンサー、有望な薬剤、治験関連の最新ニュース、主要企業分析、主要な治験プロファイル分析などの情報をご提供致します。
・心臓弁膜症:主要地域別治験動向
・心臓弁膜症:アジア市場
・心臓弁膜症:ヨーロッパ市場
・心臓弁膜症:アメリカ市場
・心臓弁膜症:中南米市場
・心臓弁膜症:中東・アフリカ市場
・心臓弁膜症:段階(フェーズ)別治験件数
・心臓弁膜症:進捗状況別の治験件数
・心臓弁膜症:スポンサーの種類別治験件数
・心臓弁膜症:有望なスポンサー
・心臓弁膜症:有望な薬剤分析
・心臓弁膜症:主要企業分析
【レポートの概要】

Heart Valve Disease Global Clinical Trials Review, H2, 2017

Summary

GlobalData’s clinical trial report, “Heart Valve Disease Global Clinical Trials Review, H2, 2017″ provides an overview of Heart Valve Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Heart Valve Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Heart Valve Disease to Cardiovascular Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Heart Valve Disease to Cardiovascular Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Heart Valve Disease Therapeutics Clinical Trials 29
Prominent Drugs 30
Clinical Trial Profile Snapshots 31
Appendix 134
Abbreviations 134
Definitions 134
Research Methodology 135
Secondary Research 135
About GlobalData 136
Contact Us 136
Source 136

List of Tables
Heart Valve Disease Therapeutics, Global, Clinical Trials by Region, 2017* 7
Heart Valve Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
Heart Valve Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
Heart Valve Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 11
Heart Valve Disease Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12
Heart Valve Disease Therapeutics Clinical Trials, North America, Top Countries, 2017* 13
Heart Valve Disease Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 14
Heart Valve Disease Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 15
Proportion of Heart Valve Disease to Cardiovascular Clinical Trials, G7 Countries (%), 2017* 16
Heart Valve Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
Heart Valve Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
Proportion of Heart Valve Disease to Cardiovascular Clinical Trials, E7 Countries (%), 2017* 19
Heart Valve Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
Heart Valve Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
Heart Valve Disease Therapeutics, Global, Clinical Trials by Phase, 2017* 22
Heart Valve Disease Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 23
Heart Valve Disease Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
Heart Valve Disease Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
Heart Valve Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
Heart Valve Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 27
Heart Valve Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
Heart Valve Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 29
Heart Valve Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 30

List of Figures
Heart Valve Disease Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
Heart Valve Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
Heart Valve Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
Heart Valve Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 11
Heart Valve Disease Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12
Heart Valve Disease Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 13
Heart Valve Disease Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 14
Heart Valve Disease Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2017* 15
Proportion of Heart Valve Disease to Cardiovascular Clinical Trials, G7 Countries (%), 2017* 16
Heart Valve Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
Heart Valve Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
Proportion of Heart Valve Disease to Cardiovascular Clinical Trials, E7 Countries (%), 2017* 19
Heart Valve Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
Heart Valve Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
Heart Valve Disease Therapeutics, Global, Clinical Trials by Phase (%), 2017* 22
Heart Valve Disease Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 23
Heart Valve Disease Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
Heart Valve Disease Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
Heart Valve Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
Heart Valve Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 27
Heart Valve Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
Heart Valve Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 29
Heart Valve Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 30
GlobalData Methodology 135

【掲載企業】

AstraZeneca Plc
C. H. Boehringer Sohn AG & Co KG
Mezzion Pharma Co Ltd
Merck & Co Inc
Pfizer Inc
The Medicines Company
Sanofi
Novartis AG
Edwards Lifesciences Corp
Bayer AG

【レポートのキーワード】

心臓弁膜症、治験、臨床試験、治療薬

★調査レポート[心臓弁膜症:世界の治験レビュー(2017年下半期版)] (コード:GDHC4545CTIDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[心臓弁膜症:世界の治験レビュー(2017年下半期版)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆